The DGN recently presented a new S2k guideline for Parkinson’s disease. This guideline addresses important topics relating to the diagnosis and treatment of Parkinson’s disease. In the past, the terms “Parkinson’s disease” and “idiopathic Parkinson’s syndrome” were often used interchangeably. The new guideline now recommends the more general term “Parkinson’s disease”, as many cases of the disease are caused by genetic variants and are therefore not idiopathic in nature.
Focal points of the Parkinson’s guideline
One of the main focuses of the guideline is on diagnosis. It is recommended that the severity of non-motor symptoms should be taken into account when making the diagnosis in order to assess the prognosis. Cranial magnetic resonance imaging should also be performed early in the course of the disease for differential diagnosis. If a patient requests it, a diagnostic genetic test should also be offered, especially if there is a family history of Parkinson’s or if the symptoms of the disease manifest themselves before the age of 50.
Therapy recommendations
The guideline also provides instructions for the drug treatment of Parkinson’s disease. The same drug therapy recommendations apply to both monogenic and genetically complex Parkinson’s disease. Invasive procedures, such as deep brain stimulation, are also possible in monogenic Parkinson’s disease and can be considered if impairing levodopa-dependent fluctuations in effect occur that cannot be sufficiently improved by optimising oral or transdermal therapy.
Role of Parkinson’s patients
An important point of the guideline is the involvement of patients in the decision-making process. The decision in favour of a particular procedure should take into account not only the effectiveness on motor symptoms but also non-motor symptoms and patient characteristics as well as the patient’s individual preference. Patients should be informed about the possibility of invasive treatments at the latest when the first fluctuations occur.
Summary of the new Parkinson’s disease guideline
The DGN’s new S2k guideline is an important step towards improving the diagnosis and treatment of Parkinson’s disease in Germany. The recommendations provided will enable doctors to make better-informed decisions and ensure effective, patient-centred care. With the opportunity to comment on the guideline until 24 October, the DGN is also providing a platform for feedback and further discussion among experts, which can help to further improve the guideline and ultimately improve patient care.
About the DGN:
The German Society of Neurology (DGN) is a leading professional society in Germany specialising in the field of neurology. It serves as a platform for the exchange and further development of expertise in order to ensure optimal patient care.
About guidelines:
Medical guidelines, on the other hand, are systematically developed recommendations that help doctors and patients make decisions about appropriate healthcare in specific clinical circumstances.
Picture: Mitrey / Pixabay
More about us